Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Inclusion Criteria:

• Histologically confirmed diagnosis of 1 of the following:

  • Invasive ovarian epithelial cancer
  • Primary peritoneal cavity cancer
  • Fallopian tube cancer
• Federation of Gynecology and Obstetrics (FIGO) stage III or IV disease

• The following histologic cell types are allowed:

  • Serous adenocarcinoma
  • Mucinous adenocarcinoma
  • Endometrioid adenocarcinoma
  • Clear cell adenocarcinoma
  • Transitional cell carcinoma
  • Mixed epithelial carcinoma
  • Undifferentiated carcinoma
  • Adenocarcinoma not otherwise specified
  • Malignant Brenner tumor

• The following histologic cell types are not allowed:

  • Carcinosarcoma (i.e., malignant mixed Müllerian tumor)

  • Borderline epithelial tumors (i.e., low malignant potential or atypical proliferative tumors)

    • Patients with a prior diagnosis of a borderline tumor that was surgically resected who subsequently develop an unrelated, new, invasive ovarian epithelial or peritoneal primary cancer are eligible provided patient received no prior chemotherapy for any ovarian tumor
• Newly diagnosed disease AND planning to receive primary chemotherapy
• Has undergone full surgical staging
• No recurrent invasive ovarian epithelial cancer treated with surgery only (e.g., stage IA or IB low-grade lesions)

• No synchronous primary endometrial cancer or prior endometrial cancer unless all of the following criteria are met:

  • Stage IA or IB disease
  • Superficial myometrial invasion without vascular or lymphatic invasion
  • No poorly differentiated subtypes (e.g., papillary serous, clear cell, or other FIGO grade 3 lesions)
• No other invasive malignancies within the past 5 years except for nonmelanoma skin cancer
• No rheumatoid arthritis, severe uncontrolled osteoarthritis, hepatic fibrosis, or other active chronic inflammatory condition
• No neoadjuvant chemotherapy prior to surgical staging
• More than 3 years since prior adjuvant chemotherapy for localized breast cancer AND no recurrent or metastatic disease
• No prior cancer treatment that contraindicates study therapy
• No prior chemotherapy for any abdominal or pelvic tumor